A15451 | Pages: NA | Jul 2022 | 126 Views | | |
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Menstrual Cramps Treatment Market
Request Now !Dysmenorrhea is a clinical term for menstrual cramps, in which females experience severe pains in the lower abdomen that can migrate to the lower legs and the back. A majority of women experience dysmenorrhea during puberty, usually within four to five years of their first menstrual cycle. Prostaglandins are substances that are produced in the uterine lining during menstruation, which generate muscle contractions in the uterus, causing pain and reducing blood and oxygen flow to the uterus. Menstrual problems can be caused by a wide range of underlying diseases. To establish the cause, physicians often rely on the patient's medical history, physical examination, and laboratory tests, which pinpoints the exact reason for menstruation irregularity and allows the doctor to plan an appropriate treatment.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments are working to address the COVID-19 outbreak globally, from supporting the development of vaccines to planning for medicine supply chain challenges.
Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Furthermore, the implementation of lockdown due to the COVID-19 pandemic has delayed the treatment for menstrual cramps; thereby, having a negative impact on the market. This was attributed to the fact that due to the COVID-19 pandemic many hospitals across the globe were restructured to increase hospital capacity for patients diagnosed with COVID-19. This in turn is expected to have a significant impact on the menstrual cramps treatment market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish Menstrual Cramps Treatment Market
In July 2020, Teva Pharmaceuticals USA, Inc., which holds Takeda in
a joint business venture in the Japanese market, announced a new strategy for its local commercial operations. This strategy has enhanced the company's presence in the Japanese market and propels its revenue growth.
In March 2018, GlaxoSmithKline Plc. declared a successful agreement with Novartis to acquire full ownership of the consumer healthcare business. This agreement helped the company to escalate its product portfolio and revenue growth of the company.
In January 2021, Pfizer, Inc. and Myovant Sciences announced a positive phase 3 spirit extension study of once-daily relugolix combination therapy in women with endometriosis. The therapy reported clinically meaningful reductions in dysmenorrhea.
In September 2019, Bayer announced data demonstrating a single maximum non-prescription dose of Aleve provided more pain relief over 12 hours than acetaminophen for menstrual cramps due to primary dysmenorrhea.
Key Benefits of Report
Questions Answered in Menstrual Cramps Treatment Market Report
Key Market Segments
Segments | Sub-segments |
---|---|
By Type |
|
By Treatment |
|
By Mode of Prescription |
|
By Route of Administration |
|
By End User |
|
By Region |
|
Key Market Players
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers